A
Ana Giménez-Capitán
Researcher at Laboratory of Molecular Biology
Publications - 63
Citations - 1854
Ana Giménez-Capitán is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 21, co-authored 49 publications receiving 1457 citations. Previous affiliations of Ana Giménez-Capitán include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
Carlota Costa,Miguel Angel Molina,Ana Drozdowskyj,Ana Giménez-Capitán,Jordi Bertran-Alamillo,Niki Karachaliou,Radj Gervais,Bartomeu Massuti,Jia Wei,Teresa Moran,Margarita Majem,Enriqueta Felip,Enric Carcereny,Rosario García-Campelo,Santiago Viteri,Miquel Taron,Mayumi Ono,Petros Giannikopoulos,Trever G. Bivona,Rafael Rosell +19 more
TL;DR: Low-level pretreatment T790M mutations can frequently be detected and can be used for customizing treatment with T790m-specific inhibitors and can potentially be used as a biomarker of survival in EGFR-mutant NSCLC and for synthetic lethality therapies.
Journal ArticleDOI
KRAS Mutations in Lung Cancer
Niki Karachaliou,Clara Mayo,Carlota Costa,Ignacio Magri,Ana Giménez-Capitán,Miguel Angel Molina-Vila,Rafael Rosell +6 more
TL;DR: The clinical and pathologic characteristics of patients with NSCLC and with KRAS mutations are summarized, work that explores the predictive and prognostic influence ofKRAS mutations is described, and an overview of the "synthetic lethal" interactions and current approaches to targeting KRAS-mutant NSCLc is provided.
Journal ArticleDOI
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Niki Karachaliou,Maria Gonzalez-Cao,G. Crespo,Ana Drozdowskyj,Erika Aldeguer,Ana Giménez-Capitán,Cristina Teixidó,Miguel Angel Molina-Vila,Santiago Viteri,Maria de los Llanos Gil,Salvador Martin Algarra,Elisabeth Pérez-Ruiz,Ivan Marquez-Rodas,Delvys Rodriguez-Abreu,Remedios Blanco,Teresa Puertolas,Maria Angeles Royo,Rafael Rosell +17 more
TL;DR: IFN-γ is an important marker for prediction of response to immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients and is warranted in order to validate whether IFNG is more accurate than PD-L1.
Journal ArticleDOI
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
R. Jonas A. Nilsson,Niki Karachaliou,Jordi Berenguer,Ana Giménez-Capitán,Pepijn Schellen,Cristina Teixidó,Jihane Tannous,Justine L. Kuiper,Esther Drees,Magda Grabowska,Marte van Keulen,Daniëlle A.M. Heideman,Erik Thunnissen,Anne-Marie C. Dingemans,Santiago Viteri,Bakhos A. Tannous,Ana Drozdowskyj,Rafael Rosell,Egbert F. Smit,Thomas Wurdinger +19 more
TL;DR: Platelets are a valuable source for the non-invasive detection of EML4-ALK rearrangements and may prove useful for predicting and monitoring outcome to crizotinib, thereby improving clinical decisions based on radiographic imaging alone.
Journal ArticleDOI
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Kirstine Jacobsen,Jordi Bertran-Alamillo,Miguel Angel Molina,Cristina Teixidó,Niki Karachaliou,Martin Haar Pedersen,Josep Castellví,Mónica Garzón,Carles Codony-Servat,Jordi Codony-Servat,Ana Giménez-Capitán,Ana Drozdowskyj,Santiago Viteri,Martin R. Larsen,Ulrik Lassen,Enriqueta Felip,Trever G. Bivona,Henrik J. Ditzel,Henrik J. Ditzel,Rafael Rosell +19 more
TL;DR: It is shown that resistant tumors display high Akt activation and that a combined treatment with AKT inhibitors causes synergistic tumour growth inhibition in vitro and in vivo.